We also observed a similar impairment in PARP cleavage and reduced TUNEL staining in SUP-M2 and SR cells lines expressing GzB shRNA following treatment with doxorubicin (Figure 5), a component of the combination chemotherapy used to treat patients with ALK+ ALCL [37–39]. Here, ALK is linked to anaplastic large cell lymphoma.